Patents Assigned to Fred Hutchinson Cancer Research Center
  • Publication number: 20110059012
    Abstract: This invention provides, among other things, methods for the identification and isolation of viable putative long-lived antigen-specific memory CD8+ T cell subsets (CMhi and EMhi) with high surface expression of CD161 and/or IL-18R? and the capacity to rapidly efflux the fluorescent dye Rh123.
    Type: Application
    Filed: January 28, 2009
    Publication date: March 10, 2011
    Applicant: Fred Hutchinson Cancer Research Center
    Inventors: Cameron J Turtle, Stanley R. Riddell
  • Patent number: 7892770
    Abstract: In a wide variety of human solid tumors, an aggressive, metastatic phenotype and poor clinical prognosis are associated with expression of the receptor tyrosine kinase Met. Disclosed herein are (a) a monoclonal antibody named Met4, which antibody is specific for Met, and (b) a hybridoma cell line that produces Met4. The Met4 antibody is particularly useful for detecting Met in formalin-fixed tissue. Methods of using the Met4 antibody for detection, diagnosis, prognosis, and evaluating therapeutic efficacy are provided.
    Type: Grant
    Filed: August 24, 2007
    Date of Patent: February 22, 2011
    Assignees: Van Andel Research Institute, Fred Hutchinson Cancer Research Center
    Inventors: Boliang Cao (Brian), George F. Vande Woude, Beatrice S. Knudsen
  • Publication number: 20100316650
    Abstract: The present invention provides prognostic and diagnostic methods for cancer, as well as methods for monitoring or staging cancer. Methods involve assaying for tumor-derived soluble MIC polypeptide—either MICA or MICB or both—in a sample from a subject. Assays can be implemented with a MIC polypeptide binding agent such as a MIC polypeptide antibody or recombinantNKG2D. An ELISA sandwich assay is employed in some embodiments of the invention to identify a soluble MIC polypeptide. In additional embodiments, a sample is assayed for tumor cell-surface bound MIC in addition to assaying for soluble MIC. The invention also provides methods of cancer therapy involving detecting cancer in the subject by assaying for soluble MIC polypeptide and then administering a cancer therapy.
    Type: Application
    Filed: July 2, 2010
    Publication date: December 16, 2010
    Applicant: Fred Hutchinson Cancer Research Center
    Inventors: Thomas Spies, Veronika Spies
  • Publication number: 20100273151
    Abstract: The present disclosure provides methods for detecting the genome-wide presence of methylated DNA and palindrome formation. The present disclosure also provides methods for specific enrichment of methylated DNA or DNA having a DNA palindrome. These methods have demonstrated that somatic palindromes and methylated DNA occur frequently and are widespread in human cancers. Individual tumor types have a characteristic non-random distribution of palindromes in their genome and a small subset of the palindromic loci are associate with gene amplification. The disclosed method can be used to define the plurality of genomic DNA palindromes and regions having methylated DNA associated with various tumor types and can provide methods for the classification of tumors, and the diagnosis, early detection of cancer as well as the monitoring of disease recurrence and assessment of residual disease.
    Type: Application
    Filed: May 26, 2009
    Publication date: October 28, 2010
    Applicant: Fred Hutchinson Cancer Research Center
    Inventors: Stephen J. Tapscott, Hisashi Tanaka, Meng-Chao Yao, Scott J. Diede
  • Publication number: 20100273169
    Abstract: Provided are quantitative PCR-based compositions and methods for the diagnosis of invasive pulmonary aspergillosis (IPA) in a patient sample, such as bronchoalveolar lavage (BAL) fluid. The methods presented herein involve isolating a patient sample, optionally extracting DNA from the sample, carrying out a quantitative PCR (qPCR) reaction on the sample to generate an amplicon that includes a region of an Aspergillus spp. ribosomal RNA (rRNA) gene, and detecting the PCR amplicon. The present disclosure also provides primers and primer sets for specifically detecting an Aspergillus spp. fungal pathogen in the presence of human ribosomal DNA (rDNA).
    Type: Application
    Filed: April 27, 2010
    Publication date: October 28, 2010
    Applicant: FRED HUTCHINSON CANCER RESEARCH CENTER
    Inventors: DAVID N. FREDRICKS, PRASANNA D. KHOT, DAISY L. KO
  • Patent number: 7795411
    Abstract: The present invention provides compositions and methods for generating in vivo biotinylated, secreted recombinant polypeptides comprising recombinantly co-expressing in a yeast cell (a) a secreted recombinant polypeptide comprising a biotin accepting site; and (b) a biotin ligase fused to the golgi localization domain so that the biotin ligase is localized to the golgi of the yeast cell where it acts on the biotin-accepting site of the secreted polypeptide as it transits the secretory system.
    Type: Grant
    Filed: January 31, 2007
    Date of Patent: September 14, 2010
    Assignee: Fred Hutchinson Cancer Research Center
    Inventors: Nathalie Scholler, Barbara Garvik
  • Publication number: 20100221709
    Abstract: The present invention provides methods and combinations of methods for identifying agents that modulate the apoptotic state of a cell by binding to the hydrophobic groove of a Bcl-2 family member anti-apoptotic protein. In certain embodiments, the methods generally comprise the use of Bcl-2 family member proteins having one or more mutations in the hydrophobic groove that, relative to a corresponding protein lacking the mutation, affect, e.g., binding of desired agents or in vitro antimycin sensitivity without substantially altering tertiary protein structure. In these embodiments, the methods comprise the identification of agents that exhibit reduced binding affinities and/or other biological activities for the mutant proteins relative to the corresponding Bcl-2 family member lacking the mutation.
    Type: Application
    Filed: March 9, 2009
    Publication date: September 2, 2010
    Applicant: Fred Hutchinson Cancer Research Center
    Inventors: David M. Hockenbery, Michael K. Manion
  • Publication number: 20100217534
    Abstract: In one aspect, the invention provides methods for determining the contributions of canid populations to a canid genome. The methods comprise the steps of: (a) obtaining the identity of one or both alleles in a test canid genome for each of a set of markers; and (b) determining the contributions of canid populations to the test canid genome by comparing the alleles in the test canid genome to a database comprising canid population profiles, wherein each canid population profile comprises genotype information for the set of markers in the canid populations.
    Type: Application
    Filed: April 27, 2010
    Publication date: August 26, 2010
    Applicant: FRED HUTCHINSON CANCER RESEARCH CENTER
    Inventors: Elaine Ostrander, Leonid Kruglyak, Heidi G. Parker, Lisa V. Kim, Matthew Stephens, Tiffany B. Malek, Nathan B. Sutter, Scott Carlson
  • Patent number: 7771718
    Abstract: The present invention provides prognostic and diagnostic methods for cancer, as well as methods for monitoring or staging cancer. Methods involve assaying for tumor-derived soluble MIC polypeptide—either MICA or MICB or both—in a sample from a subject. Assays can be implemented with a MIC polypeptide binding agent such as a MIC polypeptide antibody or recombinant NKG2D. An ELISA sandwich assay is employed in some embodiments of the invention to identify a soluble MIC polypeptide. In additional embodiments, a sample is assayed for tumor cell-surface bound MIC in addition to assaying for soluble MIC. The invention also provides methods of cancer therapy involving detecting cancer in the subject by assaying for soluble MIC polypeptide and then administering a cancer therapy.
    Type: Grant
    Filed: April 22, 2003
    Date of Patent: August 10, 2010
    Assignee: Fred Hutchinson Cancer Research Center
    Inventors: Thomas Spies, Veronika Spies
  • Publication number: 20100166754
    Abstract: The present invention relates to methods of treating immune disorders, particularly autoimmune and inflammatory disorders such as rheumatoid arthritis, and methods of producing antibodies for use in therapeutic strategies for treating such disorders. Generally, the present methods involve the use of antibodies that specifically bind to NKG2D receptors present on the surface of cells underlying the disorders.
    Type: Application
    Filed: December 30, 2009
    Publication date: July 1, 2010
    Applicant: Fred Hutchinson Cancer Research Center
    Inventors: Thomas Spies, Veronika Spies
  • Patent number: 7729863
    Abstract: In one aspect, the invention provides methods for determining the contributions of canid populations to a canid genome. The methods comprise the steps of: (a) obtaining the identity of one or both alleles in a test canid genome for each of a set of markers; and (b) determining the contributions of canid populations to the test canid genome by comparing the alleles in the test canid genome to a database comprising canid population profiles, wherein each canid population profile comprises genotype information for the set of markers in the canid populations.
    Type: Grant
    Filed: December 15, 2004
    Date of Patent: June 1, 2010
    Assignee: Fred Hutchinson Cancer Research Center
    Inventors: Elaine Ostrander, Leonid Kruglyak, Heidi G Parker, Lisa V Kim, Matthew Stephens, Tiffany B Malek, Nathan B Sutter, Scott Carlson
  • Publication number: 20100129821
    Abstract: Disclosed herein are methods for detecting a fungal pathogen in a patient sample, involving isolating the sample, carrying out a PCR reaction on the sample to generate an amplicon that includes a region of the fungal 28S ribosomal RNA gene, and detecting the PCR amplicon. Also disclosed are sequences of primers for specifically detecting a broad range of fungal pathogens in the presence of human ribosomal DNA. In certain embodiments, the amplicon is detected by sequencing or by two-dimensional melt-curve analysis. In yet other embodiments, more than one fungal pathogen is detected in a sample using the methods disclosed herein.
    Type: Application
    Filed: November 24, 2009
    Publication date: May 27, 2010
    Applicant: Fred Hutchinson Cancer Research Center
    Inventors: David N. Fredricks, Prasanna D. Khot, Daisy L. Ko
  • Patent number: 7666417
    Abstract: The present invention relates to methods of treating immune disorders, particularly autoimmune and inflammatory disorders such as rheumatoid arthritis, and methods of producing antibodies for use in therapeutic strategies for treating such disorders. Generally, the present methods involve the use of antibodies that specifically bind to NKG2D receptors present on the surface of cells underlying the disorders.
    Type: Grant
    Filed: July 23, 2004
    Date of Patent: February 23, 2010
    Assignee: Fred Hutchinson Cancer Research Center
    Inventors: Thomas Spies, Veronika Spies
  • Publication number: 20100021387
    Abstract: The present invention concerns compositions and methods involving incubating biological materials under hypoxic or anoxic conditions to induce stasis or suspended animation. Methods of screening for compounds that induce stasis or compounds that increase the ability to undergo stasis are included. Such methods have ramifications for preserving biological materials as well as reducing or preventing trauma to biological materials. Also contemplated are methods for screening compounds that are active or more active under hypoxic conditions than normoxic conditions. Such methods can be used to identify antitumor compounds that would operate under hypoxic conditions in which tumor cells survive.
    Type: Application
    Filed: June 4, 2009
    Publication date: January 28, 2010
    Applicant: FRED HUTCHINSON CANCER RESEARCH CENTER
    Inventors: Mark B. Roth, Pamela A. Padilla
  • Patent number: 7625704
    Abstract: The present invention provides methods and compositions for identifying bacteria associated with bacterial vaginosis and diagnosing bacterial vaginosis in a subject.
    Type: Grant
    Filed: December 1, 2006
    Date of Patent: December 1, 2009
    Assignee: Fred Hutchinson Cancer Research Center
    Inventors: David N. Fredricks, Tina Fiedler
  • Patent number: 7615350
    Abstract: The present invention provides a novel method for specifically isolating and separating large segments of genomic DNA that can subsequently be used to determine a genomic haplotype. The invention relies on using a solid phase having a flat surface arrayed with oligonucleotides designed to specifically hybridize to each particular haplotype of an individual sample, e.g., oligonucleotides designed to specifically hybridize with each of the two HLA-B haplotypes, HLA-A, HLA-C, HLA-DR, HLA-DQ, and the like. The genomic DNA is contacted and hybridized to the arrayed oligonucleotides to form a genomic DNA/oligonucleotide complex. The excess genomic DNA is washed away and the haplotype separated genomic DNA is denatured from the oligonucleotide probe and collected. The method of the present invention allows for the separation of genomic DNA fragments of between approximately 2 to about 4 megabases (Mb).
    Type: Grant
    Filed: October 19, 2007
    Date of Patent: November 10, 2009
    Assignees: Fred Hutchinson Cancer Research Center, Institute for Systems Biology
    Inventors: Effie W. Petersdorf, Zhen Guo, Leroy Hood
  • Patent number: 7560117
    Abstract: The present invention relates to a highly processive reverse transcriptase having DNA polymerase activity and substantially reduced protease activity. More specifically, the invention relates to an isolated reverse transcriptase from foamy virus comprising a substantially inactivated protease. The invention also relates to vectors containing the gene and hosts transformed with the vector of the invention. Further, the invention relates to a method for producing reverse transcriptase having DNA polymerase activity and substantially reduced protease activity by expressing the reverse transcriptase genes of the present invention in a recombinant host. Methods are also provided for producing cDNA from polynucleotides using the highly processive reverse transcriptase of the invention. Kits for the preparation of cDNA from RNA comprising the highly processive reverse transcriptase of the invention are also provided.
    Type: Grant
    Filed: May 22, 2002
    Date of Patent: July 14, 2009
    Assignee: Fred Hutchinson Cancer Research Center
    Inventors: Stephen Hughes, Paul Boyer, Maxine Linial, Carolyn Stenbak, Patrick Clark
  • Patent number: 7560610
    Abstract: Hypercellular nonhuman organisms have functionally inactivated expression of a cyclin inhibitor gene, especially p27. The growth rate of nonhuman organisms are increased such that a desired size is attained more quickly than as compared to nonvariant organisms. Inhibitors of the p27 cyclin dependent kinase inhibitor protein or sequences encoding the protein modulate vertebrate cell cycle progression and increase the proportion of dividing cells to non-dividing cells in a population of treated cells. As the proportion of dividing cells increases, the cell population, e.g., hematopoietic progenitor (stem) cells, is more efficiently used for gene therapy applications. Transgenic animals and plants, and knockout alleles are provided.
    Type: Grant
    Filed: April 3, 2003
    Date of Patent: July 14, 2009
    Assignee: Fred Hutchinson Cancer Research Center
    Inventors: James M. Roberts, Steven R. Coats, Matthew L. Fero
  • Publication number: 20090099035
    Abstract: Arrays of HLA Class I oligonucleotide probes on a solid support are provided, wherein the probes are sufficient to represent at least 80% of the known polymorphisms in exons 2 and 3 of the HLA Class I locus.
    Type: Application
    Filed: November 25, 2008
    Publication date: April 16, 2009
    Applicants: Fred Hutchinson Cancer Research Center, The University of Washington
    Inventors: Effie W. Petersdorf, Zhen Guo, John A. Hansen, Leroy Hood
  • Patent number: 7514406
    Abstract: A method for identifying a compound that inhibits the NAD+-dependent deacetylase activity of a SIR2 protein is disclosed. These compounds are useful for the treatment of cancers and other diseases, through the activation of silenced genes, through the promotion of apoptosis in cancerous cells, and through the inhibition of transcriptional repressor activity in oncogenes.
    Type: Grant
    Filed: November 26, 2002
    Date of Patent: April 7, 2009
    Assignee: Fred Hutchinson Cancer Research Center
    Inventors: Antonio Bedalov, Daniel E. Gottschling, Julian Simon